S574
Clinical – Head & neck
ESTRO 2026
Keywords: neck fibrosis, PORT, CRT
stages (T1/T2 vs T3/T4), and N-stages (N0/N1 vs N2/N3) indicated no statistically significant mortality differences between patients undergoing concomitant chemotherapy and those getting radiotherapy alone (log-rank p = 0.113). Multivariate Cox regression analysis demonstrated that concurrent chemotherapy following neoadjuvant treatment did not substantially influence overall survival (HR = 0.713, p = 0.619). Furthermore, none of the other clinical variables, including age (HR = 1.041, p = 0.087), gender (HR = 0.918, p = 0.904), T-stage grouping (T1/T2 vs T3/T4) (HR = 1.154, p = 0.814), N-stage grouping (N0/N1 vs N2/N3) (HR = 1.863, p = 0.404), radiotherapy technique (HR = 0.697, p = 0.596), BED (HR = 0.961, p = 0.257), or radiotherapy duration (HR = 0.990, p = 0.776), demonstrated statistically significant associations with survival outcomes.
Digital Poster 1743 The effect of adding concurrent chemotherapy to radiotherapy following neoadjuvant chemotherapy in patients with nasopharyngeal carcinoma Reza Ghalehtaki 1,2 , Ali Kazemian 1 , Farshid Farhan 1 , Mahdi Aghili 1 , Kasra Kolahdouzan 1,2 , Ehsan Saraee 3,2 1 Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of. 2 Radiation Oncology Research Center, Cancer Research Institute, IKHC, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of. 3 Department of Radiation Oncology, Yas Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of Purpose/Objective: This study aims to evaluate whether adding concurrent chemotherapy to radiotherapy after neoadjuvant chemotherapy improves survival outcomes in patients with nasopharyngeal carcinoma [1]. The objective is to determine optimal treatment sequencing while balancing efficacy and toxicity, and to identify patient subgroups that benefit most [2]. Material/Methods: This retrospective cohort study included all patients diagnosed with nasopharyngeal carcinoma and treated at the Cancer Institute of Iran between March 2007 and March 2024. Included patients had biopsy- confirmed carcinoma and were treated with radical- intent radiotherapy. All patients received neoadjuvant chemotherapy. Exclusion criteria were prior head and neck radiotherapy, distant metastasis at presentation, incomplete treatment. Survival outcomes were evaluated using Cox regression and Kaplan-Meier methods. A significance level of 0.05 was used for all tests. Results: A total of 90 patients with nasopharyngeal carcinoma were included in this retrospective analysis. The mean age was 46.79 years (±SD = 15.7) (Table 1). Sixty-nine patients (76.7%) subsequently received concurrent chemotherapy with radiotherapy, while 21 patients (23.3%) received radiotherapy alone (BED of 82.3Gy (38.4-86.4)). The median Follow up time for the total population was 31.0 months (95% CI: 23.065-38.935). The 3-year OS rate for patients who did not receive concurrent chemotherapy was 58% (95% CI: 26.64 - 89.36), whereas it was 83% (95% CI: 73.2 - 92.8) for those who did. The log-rank test that compared the survival distributions of the two groups did not find a statistically significant difference ( χ² = 1.447, p = 0.229). Subgroup analysis by tumor stages (II vs III/IV), T-
Conclusion: A retrospective study of 90 nasopharyngeal carcinoma patients receiving neoadjuvant chemotherapy found no statistically significant survival benefit from adding concurrent chemotherapy to radiotherapy across all comparative analyses performed. References: [1] Wang, M., Tian, H., Li, G., et al. (2016). Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget, 7(30), 48375- 48390. https://doi.org/10.18632/ONCOTARGET.10237[ 2] Ji, P., Chen, X., Peng, X., et al. (2023). Individualized concurrent chemotherapy for patients with stage III-
Made with FlippingBook - Share PDF online